Home » Blog » Helpline for Diabetics Complications with Actos Actos Bladder Cancer Lawyers
Helpline for Diabetics Complications with Actos Actos Bladder Cancer Lawyers
Posted by lisaspitzer on Sep 21, 2011 in Blog | 0 comments
The News On Actos class action Continues. Actos lawyers,Actos Diabetes Drug,actos lawsuits
The Irish Medical Times summarized the findings of several studies and concluded that there is an increased risk between the use of Actos and Bladder Cancer:
"There is a small increased risk of bladder cancer with the use of pioglitazone [Actos]; epidemiological data suggest a relative risk of around 1.2 (ranging from 1.15 to 1.33 for ever use across studies). Source: Pioglitazone,New contra-indications and warnings"………… Irish Medical Times
The patients with the highest risk of developing bladder cancer from Actos appear to be those who are taking the highest doses for the longest period of time. Patients who have been taking Actos for one year or longer seem to be at the highest risk of developing bladder cancer.
Scientists at the FDA and at the European equivalents of the FDA are still examining data and looking at the link between Actos and bladder cancer. The studies are strong enough that Jewish Lawyer Network Attorney"s for Actos are currently taking Actos cases. For More Information call the Jewish Lawyer Network Actos Helpline
Both the United States Food & Drug Administration (FDA), as well as its European counter-part, the European Medicines Agency (EMA), have recently issued warnings which have both doctors and users of the Type 2 Diabetes drug Actos (Pioglitazone) extremely concerned.
As of June 10, 2011 doctors in France and Germany have been instructed not to proscribe the drug Actos to their patients and the drug Actos has actually been removed from pharmacy shelves. The reason for these actions is because recent studies have shown that an patients who use the drug Actos to treat their Type 2 Diabetes by using Actos are more likely to contract bladder cancer.
What makes this fact more difficult to accept is that it appears that the incidence of Bladder Cancer in people using the drug Actos, was known to the drug manufacturer Takeda, Inc. in the clinical trials However, even though, Takeda, Inc. apparently knew that the drug Actos would cause bladder cancer, it still marketed and sold 2.3 million prescriptions for the drug Actos in the United States in one year alone. 2010. The active ingredient in Actos, Pioglitazone, is also used in ActoPlus met, ActoPlus met XR and Duetac to treat Type 2 Diabetes.
On June 15, 2011, the FDA issued an urgent health warning to users and prescribers of the drug Actos acknowledging the recent statistical data that shows up to a 40% increase in risk for bladder cancer in users of Actos. The studies further show that the risk of bladder cancer increases with higher dosages and longer courses of treatment with Actos.
After the health warning was issued the FDA will now require that these recent findings and risks be included in warnings attached to the drug packaging and future marketing materials. The FDA is also going to continue monitor the data being released by various ongoing studies into the long term health effects of Actos (Pioglitazone). In the meantime, Actos remains available to consumers in the United States despite these newfound risks.
Actos® is primarily used to control type 2 diabetes by increasing the body’s sensitivity to insulin. Type 1 diabetes, often called, “juvenile diabetes,” is characterized by the body not producing insulin to counteract glucose in the blood. Blood sugar then becomes excessive and major damage to organs and tissues occurs. Type 2 diabetes generally affects adults and older people and is characterized by the body producing insulin but the cells of the body rejecting the insulin resulting in the same type of glucose damage to organs and tissues. Pioglitazone, or Actos®, causes cells and tissues to better use insulin.
Possible signs or symptoms of Actos bladder cancer may include:
Blood in the Urine
Pain During Urination
Frequent Urination
Feeling of Need to Urinate Without Results
A similar drug, Avandia, has already been removed from the market after being linked to an increased risk of heart attacks. In fact, Actos and Avandia are the only two drugs in their class, called thiazolidinediones, and work in very similar ways. in a study released August 24, 2010 Actos was found to have the same dangerous side effects as Avandia.
Both the United States Food & Drug Administration (FDA), as well as its European counter-part, the European Medicines Agency (EMA), have recently issued warnings which have both doctors and users of the Type 2 Diabetes drug Actos (Pioglitazone) extremely concerned.
As of June 10, 2011 doctors in France and Germany have been instructed not to proscribe the drug Actos to their patients and the drug Actos has actually been removed from pharmacy shelves. The reason for these actions is because recent studies have shown that an patients who use the drug Actos to treat their Type 2 Diabetes by using Actos are more likely to contract bladder cancer.
What makes this fact more difficult to accept is that it appears that the incidence of Bladder Cancer in people using the drug Actos, was known to the drug manufacturer Takeda, Inc. in the clinical trials However, even though, Takeda, Inc. apparently knew that the drug Actos would cause bladder cancer, it still marketed and sold 2.3 million prescriptions for the drug Actos in the United States in one year alone. 2010. The active ingredient in Actos, Pioglitazone, is also used in ActoPlus met, ActoPlus met XR and Duetac to treat Type 2 Diabetes.
On June 15, 2011, the FDA issued an urgent health warning to users and prescribers of the drug Actos acknowledging the recent statistical data that shows up to a 40% increase in risk for bladder cancer in users of Actos. The studies further show that the risk of bladder cancer increases with higher dosages and longer courses of treatment with Actos.
After the health warning was issued the FDA will now require that these recent findings and risks be included in warnings attached to the drug packaging and future marketing materials. The FDA is also going to continue monitor the data being released by various ongoing studies into the long term health effects of Actos (Pioglitazone). In the meantime, Actos remains available to consumers in the United States despite these newfound risks.
Actos® is primarily used to control type 2 diabetes by increasing the body’s sensitivity to insulin. Type 1 diabetes, often called, “juvenile diabetes,” is characterized by the body not producing insulin to counteract glucose in the blood. Blood sugar then becomes excessive and major damage to organs and tissues occurs. Type 2 diabetes generally affects adults and older people and is characterized by the body producing insulin but the cells of the body rejecting the insulin resulting in the same type of glucose damage to organs and tissues. Pioglitazone, or Actos®, causes cells and tissues to better use insulin.
Possible signs or symptoms of Actos bladder cancer may include:
Blood in the Urine
Pain During Urination
Frequent Urination
Feeling of Need to Urinate Without Results
A similar drug, Avandia, has already been removed from the market after being linked to an increased risk of heart attacks. In fact, Actos and Avandia are the only two drugs in their class, called thiazolidinediones, and work in very similar ways. in a study released August 24, 2010 Actos was found to have the same dangerous side effects as Avandia. Actos appears to cause bladder cancer in long term use. If you a loved one or someone you are a caregiver for has symptoms from long term us of Actos call 1 877 522 2123 today
